Passionate about IP! Since June 2003 the IPKat has covered copyright, patent, trade mark, designs, info-tech and confidentiality issues from a mainly UK and European perspective. Read, post comments and participate!

The team is Eleonora Rosati, Annsley Merelle Ward and Merpel. E-mail the Kats here!

The team is joined by GuestKats Söğüt Atilla, Oliver Fairhurst, Claire Gregg, Georgia Jenkins and Marcel Pemsel.

SpecialKats: Verónica Rodríguez Arguijo (TechieKat), Rose Hughes (PatKat) and Jocelyn Bosse (Book Review Editor).

InternKats: Wissam Bentazar, Simone Lorenzi and Kliment Markov.
Results for obvious to try
Mechanistic insights supporting the sufficiency and inventive step of a therapeutic use (without clinical data) (T 1601/22) Mechanistic insights supporting the sufficiency and inventive step of a therapeutic use (without clinical data) (T 1601/22) Reviewed by Dr Rose Hughes on Friday, January 02, 2026 Rating: 5
Sufficiency at the priority date: A study protocol is not "the same" as a therapeutic effect invention (T0883/23) Sufficiency at the priority date: A study protocol is not "the same" as a therapeutic effect invention (T0883/23) Reviewed by Dr Rose Hughes on Wednesday, October 29, 2025 Rating: 5
When your formulation IP is beyond compare (T 0722/24) When your formulation IP is beyond compare (T 0722/24) Reviewed by Dr Rose Hughes on Monday, August 25, 2025 Rating: 5
The criteria for the novelty and inventive step of pharmaceutical selection inventions (T 1356/21) The criteria for the novelty and inventive step of pharmaceutical selection inventions (T 1356/21) Reviewed by Dr Rose Hughes on Wednesday, December 13, 2023 Rating: 5
Second medical use dosage regimen claim successfully traverses both insufficiency and "obvious-to-try" attacks (T 0799/16) Second medical use dosage regimen claim successfully traverses both insufficiency and "obvious-to-try" attacks (T 0799/16) Reviewed by Dr Rose Hughes on Monday, March 08, 2021 Rating: 5
Canadian Federal Court considers whether Teva's COPAXONE second medical use patents were obvious-to-try (Teva v Pharmascience) Canadian Federal Court considers whether Teva's COPAXONE second medical use patents were obvious-to-try (Teva v Pharmascience) Reviewed by Dr Rose Hughes on Monday, January 25, 2021 Rating: 5
The English approach to obviousness - It all depends on the facts? The English approach to obviousness - It all depends on the facts? Reviewed by Darren Smyth on Thursday, September 22, 2016 Rating: 5
Mr Justice Carr tackles plausibility in Actavis v Eli Lilly ADHD dispute (Part II) Mr Justice Carr tackles plausibility in Actavis v Eli Lilly ADHD dispute (Part II) Reviewed by Annsley Merelle Ward on Thursday, December 24, 2015 Rating: 5
Subscribe to: Posts ( Atom )
Powered by Blogger.